Lazard Asset Management LLC Akebia Therapeutics, Inc. Transaction History

Lazard Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.27 - $2.24 $55,302 - $97,540	43,545 New	43,545 $79,000
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $14,273 - $78,113	-5,972 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $39,833 - $81,099	5,972 New	5,972 $81,000
Q4 2019 Feb 13, 2020	SELL	$3.16 - $6.73 $8,358 - $17,800	-2,645 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $9,389 - $14,283	2,645 New	2,645 $10,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.